Cyient DLM Ltd Q1 FY2026 Concall Summary & Transcript Notes

Source transcript PDF: https://www.stockscans.in/document/loumwc7oiq9z338g3qvl5gyh.pdf

# 1. Financial Performance

## A. Key Figures
   * Revenue: ₹2,784 Mn (+8%) · Stand-alone down ~20% YoY
   * EBITDA: ₹251 Mn (+25.3%) with +125 bps margin expansion
   * Gross Margin: ~40% (improved Y-o-Y and sequentially, driven by revenue mix)
   * PAT: ₹75 million (2.7% margin)
   * Free Cash Flow: **₹80 Cr** consolidated · **>₹80 Cr** from Cyient DLM

## B. Revenue Growth
   *   **Growth Dynamics:** Q1 revenue growth moderated due to lapping a large prior-year defense order and Middle East-related timing delays, though no revenue loss is expected.
   *   **Stand-alone Pressure:** Stand-alone revenue decline reflects the absence of a lumpy prior-year order, masking underlying operational stability.
   *   **Cyient DLM Strength:** Subsidiary delivered robust performance with strong order intake, margin expansion, and **over ₹80 Cr in free cash flow**, signaling operational maturity.

## C. EBITDA Margin
   *   **Margin Expansion Underway:** EBITDA margin improved 125 bps despite lower revenue, driven by **favorable business mix** and structural operating leverage.
   *   **Sustainable Upside:** Management sees clear path to **double-digit EBITDA margins** this year, supported by gross margin resilience near 40% and fixed-cost absorption.
   *   **Operating Leverage Playbook:** Next **₹100 Cr in incremental revenue** expected to flow through at high gross margins with minimal indirect cost increases, given current cost base supports $400–500M revenue run rate.

## D. Cash Flow
   *   **Consistent Cash Generation:** Third straight quarter of positive free cash flow (₹2 Cr), aided by **15-day DPO improvement**, stable DSO, and lower net working capital YoY.
   *   **Working Capital Tailwinds:** Supplier and receivables management offsetting seasonal build, with customer advances holding firm.

## E. PAT & Amortization
   *   **PAT Distortion from Noncash Items:** Reported profit impacted by M&A-related **amortization of intangibles**, which depresses PAT but has no cash impact.
   *   **Other Income Drag:** Lower other income due to drawdown of IPO proceeds, a temporary headwind to YoY earnings growth.

---

# 2. Order Book & Demand

## A. Key Figures
   *   **Order Intake:** **$60 Mn** Q1 (+ highest in 8 quarters) · **₹515 Cr** Q1 (+ highest in 10 quarters)
   *   **Order Backlog:** **₹2,132 Cr** (+7 Cr QoQ)
   * Book-to-Bill Ratio: ~1.9 (highest in 8 quarters)

## B. Order Intake & Customer Momentum
   *   **Record Demand Across Segments:** Strongest quarterly order inflow in two years, driven by **new customer wins** (including Deutsche Aircraft) and broad-based traction across all three industry verticals.
   *   **Sales Engine Gaining Traction:** Management credits **deliberate sales team initiatives** and expanded market reach for robust intake, with two major BPS orders nearing closure this quarter.
   *   **Short-Term Customer Delay, Strong Underlying Trend:** Temporary pause in a key repeat order offset by overall momentum, with confidence in full-year book-to-bill **above 100%**.

## C. Backlog Composition & Visibility
   *   **High-Quality Backlog Growth:** Backlog now includes **higher-margin orders**, with ~50% of recent intake executable within FY’26, supporting revenue visibility and future margin expansion.
   *   **Balanced Sector Exposure:** Backlog split as **~40% A&D**, **9% Defense**, remainder evenly split between Industrial and Medical—mirrored in executable backlog.
   *   **No Separate Stand-Alone Reporting:** Integrated business model means no standalone backlog disclosure moving forward.

## D. RFQ Pipeline & Market Expansion
   *   **Surge in Global RFQ Activity:** Notable spike in inquiries from

---

# 3. Segment & Geography Mix

## A. Key Figures
   *   **B. S. Operations Growth:** **Industrial +425% YoY** · **Med-Tech +142% YoY**
   *   **Business Mix Shift:** **Exports declined from 60–65%** of revenue historically; **domestic (India) share rising**
   *   **Order Intake Trend:** **Domestic order intake increased** over last 18 months, with further growth expected

## B. Industrial & Med-Tech
   *   **Strategic Focus Areas:** Aerospace & Defense, Medical, and Industrial sectors represent core growth verticals with strong demand visibility.
   *   **Portfolio Stabilization:** Segment mix remains stable despite strong order book gains; pivot toward Industrial and Med-Tech post-Altek reduces cyclicality.
   *   **Underlying Growth:** Excluding legacy defense order impact, stand-alone business shows impressive momentum in targeted segments.

## C. Aerospace & Defense
   *   **Strategic Continuity:** No exit from Defense segment; active pursuit of U.S. and India opportunities despite prior-year degrowth from order completion.
   *   **Growth Enablers:** Leadership transition supports strategic push into high-reliability sectors; Altek’s U.S. footprint enhances access to defense and ADAS markets.
   *   **Portfolio De-risking:** Business mix now more balanced post-acquisition, reducing historical overreliance on volatile Defense revenues.

## D. U.S. Operations
   *   **Nearshoring Tailwinds:** Tariff uncertainty and China Plus One shift accelerating demand for U.S.-based manufacturing, benefiting Altek’s Connecticut facility.
   *   **Dual-Footprint Advantage:** India-U.S. model combines cost efficiency with local presence, enabling tariff mitigation and end-cost reduction for OEMs.
   *   **Exceptional Segment Growth:** U.S. Industrial and Med-Tech revenues surged on back of offshore-onshore operational strategy.

## E. Domestic Growth
   *   **Domestic Momentum:** India EMS market expansion fueled by PLI schemes and Industry 4.0; company sees higher growth potential in local vs. export markets.
   *   **Sales & Strategic Buildout:** Strengthened India sales team and large deal pipeline driving domestic order gains, particularly in defense.
   *   **Customer Shift:** Rising client demand for India-based manufacturing capacity reinforces strategic emphasis on domestic scale-up.

---

# 4. Capacity & Utilization

## A. Key Figures
   *   **Capacity Utilization:** **55–60%** (full-year, 2 shifts)
   *   **IPO Proceeds Deployment:** **₹60 Cr** used for working capital · **₹100 Cr** remaining (**₹60 Cr** working capital, **₹40 Cr** CAPEX)
   *   **Maintenance CAPEX:** **Minimal** expected

## B. Factory Utilization
   *   **Significant Headroom for Growth:** Current low utilization leaves substantial room to **double revenue** via third-shift addition with negligible incremental CAPEX.
   *   **Operating Leverage Intact:** High scalability expected as fixed cost base remains stable, enabling margin expansion with volume growth.

## C. Automation Progress
   *   **Digital Transformation On Track:** Factory automation and digitalization initiatives progressing toward full completion by year-end.

## D. CAPEX Outlook
   *   **Capital Discipline Maintained:** IPO fund usage aligned with RHP; remaining allocation reserved for working capital and targeted CAPEX with no near-term funding needs.

---

# 5. Product & Business Model

## A. Key Figures
   *   **B2S Revenue Contribution:** **~5%** of total revenue expected in FY '26

## B. Build-to-Spec
   *   **Strategic Growth Engine:** Build-to-spec (BTS) is a core growth and margin expansion driver, supported by a defined product roadmap and investments in technology and talent.
   *   **Pipeline Momentum:** Recent addition of **2 new accounts** with multimillion-dollar potential within 12 months, alongside a robust B2S pipeline signaling scalable future revenue.
   *   **Margin Leverage:** BTS acts as the third margin lever, with structural improvements from higher-margin NRE work, design services, and better BOM control as scale increases.

## C. Portfolio Diversification
   *   **High-Growth Verticals:** Strategic focus on capturing opportunities in renewable energy, EVs, robotics, and automation to drive long-term diversification.
   *   **Targeted Inorganic Growth:** M&A strategy prioritizes enhancing existing capabilities in PCBA, box build, and design-for-build—not gap-filling—with focus on customer proximity, regional reach, and technology.

## D. Hybrid Manufacturing
   *   **Global Supply Chain Advantage:** India-U.S. hybrid manufacturing model leveraged to capitalize on supply chain reconfiguration and deliver sustainable, innovation-led growth.

## E. Synergy Benefits
   *   **Full Integration Approach:** Acquired entity (Altek Electronics) to be operated as a single integrated unit with Cyient DLM, eliminating separate margin disclosures due to shared cost structures and synergy capture.
   *   **Composite Margin View:** Synergies across India and U.S. operations—despite differing cost bases—will create a blended margin profile, enhancing operational efficiency.

---

# 6. Risks & Geopolitical Factors

## A. Geopolitical & Operational Disruptions
   *   **Q1 Delivery Disruptions:** Airspace closures in Iran and the Gulf due to Middle East conflict forced major carriers to reroute, increasing transit times and freight costs.
   *   **Revenue Impact & Recovery:** Financial impact from Middle East challenges will be largely recouped over the year, though not fully in Q2, due to project timing constraints.
   *   **Resilient Client Response:** Strong client and supplier collaboration is helping mitigate disruptions, supporting continuity despite geopolitical volatility.

## B. Supply Chain & Strategic Adaptation
   *   **Air Freight Pressure:** Sea lane disruptions have amplified air cargo demand, tightening capacity and elevating freight expenses for the company.
   *   **Hybrid Delivery Strategy:** Pursuing optimized production footprint between India and the U.S. amid tariff uncertainty, with active RFQs reflecting client interest in flexible sourcing.

---

# 7. Guidance & Outlook

## A. Key Figures
   * Global EMS Market CAGR: 6.9% (projected to reach $1 trillion in 7 years)
   *   **Long-Term Revenue CAGR Target:** **30%** (5-year outlook, with annual variability)
   *   **Current EBITDA Margin:** **9%** (consolidated, impacted by lower revenue base) · **Teens (early to low)** expected over 2–4 years
   *   **Consolidated Margin Outlook:** Confidence in exceeding **10% margin** in FY '26

## B. Growth Drivers & Market Positioning
   *   **Favorable Macro Backdrop:** Growth outlook supported by stabilizing U.S. tariffs, China Plus One tailwinds, and rising semiconductor/electronics demand.
   *   **Strong Market Tailwinds:** Company positioned to outperform within a global EMS industry projected to double in size over the next seven years.
   *   **Robust Demand Pipeline:** Elevated RFQ activity expected to boost performance in coming quarters, with active engagement on new opportunities.

## C. Margin Trajectory & Profitability Outlook
   *   **Margin Recovery Underway:** New orders secured at significantly higher margins than prior low-margin contract, enabling profitability shift despite revenue transition.
   *   **Sustainable EBITDA Expansion:** Double-digit EBITDA margins anticipated as revenue recovers and operating leverage improves.
   *   **Solid Foundation for FY '26:** Q1 performance reflects business resilience, customer trust, and strong order backlog supporting margins and cash flow.

## D. Guidance Philosophy & Visibility
   *   **No Full-Year Revenue Guidance:** Management refrains from FY '26/FY '27 guidance, emphasizing long-term CAGR over short-term linearity.
   *   **Transition Year Dynamics:** Current fiscal marks pivot from completion of large, low-margin order to higher-margin growth phase.
   *   **Revenue Timing Uncertainty:** Monthly run-rate assumptions (e.g., ₹100 Cr/month) unreliable due to variable customer schedules, despite 18–24 month ERP visibility.
   *   **Gross Margin Stance:** No specific annualized gross margin guidance provided; current cost-to-revenue mix viewed as representative of future trends.